comparemela.com
Home
Live Updates
NeuroSense Therapeutics Rockets 283% on FDA PrimeC Study Clearance : comparemela.com
NeuroSense Therapeutics Rockets 283% on FDA PrimeC Study Clearance
By Denny Jacob
NeuroSense Therapeutics Ltd. shares rocketed 283% to $5.97 after the company said it received clearance from the Food and Drug Administration to initiate a pharmacokinetic study... | March 21, 2022
Related Keywords
Denny Jacob ,
Drug Administration ,
Neurosense Therapeutics Ltd ,
Sense Therapeutics ,
Dow Jones ,
Neurosense Therapeutics Ltd Stock Exchange ,
News ,
Information ,
Press Release ,
Y ,
Penny ,
Jacob ,
Neurosense ,
Herapeutics ,
Hares ,
Crocketed ,
O ,
After ,
The ,
Company ,
Aid ,
It ,
Eceived ,
Clearance ,
Rom ,
Wood ,
End ,
Drug ,
Administration ,
Nitiate ,
Harmacokinetic Nrsn Il0011809592 ,
comparemela.com © 2020. All Rights Reserved.